| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 152.65% | HC Wainwright & Co. | $51 → $50 | Maintains | Buy |
| 08/01/2023 | 157.71% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 06/15/2023 | 152.65% | JP Morgan | $38 → $50 | Maintains | Overweight |
| 06/08/2023 | 157.71% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 06/07/2023 | 162.76% | Wedbush | → $52 | Reiterates | Outperform → Outperform |
| 06/07/2023 | 203.18% | EF Hutton | → $60 | Reiterates | Buy → Buy |
| 06/05/2023 | 157.71% | HC Wainwright & Co. | $50 → $51 | Maintains | Buy |
| 06/05/2023 | 203.18% | EF Hutton | → $60 | Reiterates | Buy → Buy |
| 05/26/2023 | 203.18% | EF Hutton | → $60 | Reiterates | Buy → Buy |
| 05/22/2023 | 162.76% | Wedbush | → $52 | Reiterates | Outperform → Outperform |
| 04/17/2023 | 122.33% | Piper Sandler | → $44 | Assumes | → Overweight |
| 02/10/2023 | 152.65% | HC Wainwright & Co. | $48 → $50 | Reiterates | → Buy |
| 01/05/2023 | 203.18% | EF Hutton | → $60 | Initiates Coverage On | → Buy |
| 12/12/2022 | 253.71% | BMO Capital | $40 → $70 | Maintains | Outperform |
| 12/07/2022 | 71.8% | SVB Leerink | $30 → $34 | Maintains | Outperform |
| 11/04/2022 | 142.55% | HC Wainwright & Co. | $60 → $48 | Maintains | Buy |
| 10/14/2022 | 102.12% | BMO Capital | $30 → $40 | Maintains | Outperform |
| 10/03/2022 | 51.59% | SVB Leerink | $37 → $30 | Maintains | Outperform |
| 08/16/2022 | 117.28% | Piper Sandler | $44 → $43 | Maintains | Overweight |
| 08/05/2022 | 86.96% | SVB Leerink | $48 → $37 | Maintains | Outperform |
| 05/24/2022 | 162.76% | Wedbush | $59 → $52 | Maintains | Outperform |
| 05/20/2022 | 142.55% | SVB Leerink | $49 → $48 | Maintains | Outperform |
| 04/04/2022 | 97.07% | JP Morgan | $47 → $39 | Maintains | Overweight |
| 03/18/2022 | 51.59% | BMO Capital | $51 → $30 | Maintains | Outperform |
| 11/19/2021 | 162.76% | Piper Sandler | → $52 | Initiates Coverage On | → Overweight |
| 08/23/2021 | 147.6% | SVB Leerink | $55 → $49 | Maintains | Outperform |
| 08/09/2021 | 177.92% | SVB Leerink | $56 → $55 | Maintains | Outperform |
| 02/05/2021 | 203.18% | HC Wainwright & Co. | $58 → $60 | Maintains | Buy |
| 02/04/2021 | 182.97% | SVB Leerink | $57 → $56 | Maintains | Outperform |
| 11/17/2020 | 203.18% | BTIG | → $60 | Initiates Coverage On | → Buy |
| 11/10/2020 | 193.08% | HC Wainwright & Co. | $54 → $58 | Maintains | Buy |
| 11/06/2020 | 188.02% | BMO Capital | $51 → $57 | Maintains | Outperform |
| 10/15/2020 | 157.71% | BMO Capital | $40 → $51 | Maintains | Outperform |
| 10/15/2020 | 172.87% | HC Wainwright & Co. | $25 → $54 | Upgrades | Neutral → Buy |
| 10/15/2020 | 122.33% | SVB Leerink | $27 → $44 | Maintains | Outperform |
| 08/07/2020 | 36.43% | SVB Leerink | $25 → $27 | Maintains | Outperform |
| 07/01/2020 | 26.33% | HC Wainwright & Co. | → $25 | Downgrades | Buy → Neutral |
| 06/04/2020 | 26.33% | HC Wainwright & Co. | $24 → $25 | Maintains | Buy |
| 05/05/2020 | 6.11% | Barclays | → $21 | Initiates Coverage On | → Overweight |
| 01/21/2020 | 21.27% | HC Wainwright & Co. | $26 → $24 | Maintains | Buy |
| 09/04/2019 | 1.06% | Roth Capital | → $20 | Initiates Coverage On | → Buy |
| 07/23/2019 | 41.49% | Chardan Capital | → $28 | Initiates Coverage On | → Buy |
| 07/12/2019 | 31.38% | JP Morgan | $27 → $26 | Upgrades | Neutral → Overweight |
| 07/08/2019 | 31.38% | HC Wainwright & Co. | → $26 | Initiates Coverage On | → Buy |
| 04/25/2019 | 21.27% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
| 01/23/2019 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 08/14/2018 | 56.64% | BMO Capital | → $31 | Initiates Coverage On | → Outperform |
| 08/14/2018 | 31.38% | JP Morgan | → $26 | Initiates Coverage On | → Overweight |
What is the target price for Replimune Group (REPL)?
The latest price target for Replimune Group (NASDAQ: REPL) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $50.00 expecting REPL to rise to within 12 months (a possible 152.65% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Replimune Group (REPL)?
The latest analyst rating for Replimune Group (NASDAQ: REPL) was provided by HC Wainwright & Co., and Replimune Group maintained their buy rating.
When is the next analyst rating going to be posted or updated for Replimune Group (REPL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Replimune Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Replimune Group was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
Is the Analyst Rating Replimune Group (REPL) correct?
While ratings are subjective and will change, the latest Replimune Group (REPL) rating was a maintained with a price target of $51.00 to $50.00. The current price Replimune Group (REPL) is trading at is $19.79, which is out of the analyst's predicted range.